The Immunosuppressed Traveler

Infectious Disease Clinics of North America

Volumn 26, Issue 3, 2012, Pages 609-624

  Visser, L G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hematopoietic cell transplantation; HIV; Immune reconstitution; Immunocompromised; Immunosuppressive agents; Travel health information; Tumor necrosis factor antagonist; Vaccines

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; EVEROLIMUS; GLUCOCORTICOID; GOLIMUMAB; HEPATITIS A VACCINE; HYDROCORTISONE; INFLIXIMAB; MEPREDNISONE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; VACCINE; YELLOW FEVER VACCINE;

AGING; ALLERGIC DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ATOPIC DERMATITIS; B LYMPHOCYTE; BONE MARROW; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; EMPORIATRICS; ENTERITIS; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEPATITIS A; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLAMMATION; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMUS; TRAVEL; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; WOUND HEALING IMPAIRMENT; YELLOW FEVER;

B-LYMPHOCYTES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES; TRAVEL; VACCINES;

EID: 84865986518     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.06.003     Document Type: Review

References (61)

1. Recommendations of the Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization. MMWR 2011, 60(RR02):1-64.
2. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351:2715-2729.
3. Ingelfinger J.R., Schwartz R.S. Immunosuppression - the promise of specificity. N Engl J Med 2005, 353:836-838.
4. Murphy K., Travers P., Walport M. Janeway's immunobiology 2008, Garland Sciences, New York, p. 346. 7th edition.
5. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005, 353:1711-1723.
6. Perretti M., D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009, 9:62-70.
7. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10:365-376.
8. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
9. Edsbäcker S., Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004, 43:803-821.
10. Rutgeerts P., Löfberg R., Malchow H., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331:842-845.
11. Dunn C.J., Wagstaff A.J., Perry C.M., et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®)1 in organ transplantation. Drugs 2001, 61:1957-2016.
12. Hooks M.A. Tacrolimus, a new immunosuppressant-a review of the literature. Ann Pharmacother 1994, 28:501-511.
13. Thomson A.W., Turnquist H.R., Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009, 9:324-337.
14. Ferrer I.R., Araki K., Ford M.L. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011, 11:654-659.
15. Mahalati K., Kahan B.D. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001, 40:573-585.
16. Kirchner G.I., Meier-Wiedenbach I., Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004, 43:83-95.
17. de Boer N.K., van Bodegraven A.A., Jharap B., et al. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:686-694.
18. Anstey A., Lear J.T. Azathioprine; clinical pharmacology and current indications in autoimmune disorders. BioDrugs 1998, 9:33-47.
19. Ritter M.L., Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 2009, 11:290-297.
20. Struijk G.H., Minnee R.C., Koch S.D., et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010, 78:934-940.
21. Neyts J., Meerbach A., McKenna P., et al. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996, 30:125-132.
22. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
23. Grim J., Chládek J., Martínková J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003, 42:139-151.
24. Genestier L., Paillot R., Fournel S., et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998, 102(2):322-328.
25. Chan E.S., Cronstein B.N. Methotrexate-how does it really work?. Nat Rev Rheumatol 2010, 6:175-178.
26. da Mota L.M., Oliveira A.C., Lima R.A., et al. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop 2009, 42:23-27.
27. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010, 9:767-774.
28. CAMMS223 Trial Investigators, Coles A.J., Compston D.A., Selmaj K.W., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
29. Edwards J.C., Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006, 6:394-403.
30. Rehnberg M., Amu S., Tarkowski A., et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009, 11:R123.
31. Leandro M.J., Cambridge G., Ehrenstein M.R., et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620.
32. St.Clair E.W. Good and bad memories following rituximab therapy. Arthritis Rheum 2010, 62:1-5.
33. Muhammad K., Roll P., Einsele H., et al. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum 2009, 60:2284-2293.
34. van Assen S., Holvast A., Benne C.A., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
35. Pescovitz M.D., Torgerson T.R., Ochs H.D., Type 1 Diabetes TrialNet Study Group, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011, 128:1295-1302.
36. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
37. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009, 9:271-285.
38. Lobo E.D., Hansen R.J., Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004, 93:2645-2668.
39. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8:601-611.
40. Rigby W.F. Drug insight: different mechanisms of action of tumour necrosis factor antagonists - passive-aggressive behaviour?. Nat Clin Pract Rheumatol 2007, 3:227-233.
41. Visser L.G. TNF-α antagonists and immunization. Curr Infect Dis Rep 2011, 13:243-247.
42. Scheinberg M., Guedes-Barbosa L.S., Mangueira C., et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res 2010, 62:896-898.
43. Lynch H.E., Goldberg G.L., Chidgey A., et al. Thymic involution and immune reconstitution. Trends Immunol 2009, 30:366-373.
44. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9:185-194.
45. Genton B., D'Acremont V., Furrer H.J., et al. Hepatitis A vaccines and the elderly. Travel Med Infect Dis 2006, 4:303-312.
46. Roukens A.H., Soonawala D., Joosten S.A., et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 2011, 6(12):e27753.
47. Williams K.M., Hakim F.T., Gress R.E. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007, 19:318-330.
48. Krenger W., Blazar B.R., Holländer G.A. Thymic T-cell development in allogeneic stem cell transplantation. Blood 2011, 117:6768-6776.
49. Bosch M., Khan F.M., Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012, 19:324-335.
50. Ljungman P., Cordonnier C., Einsele H., Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Disease Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Diseases Canada, Centers for Disease Control and Prevention, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009, 44:521-526.
51. Gowda R., Cartwright K., Bremner J.A., et al. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol 2004, 72:299-301.
52. Yax J.A., Farnon E.C., Cary Engleberg N. Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow Fever vaccine. J Travel Med 2009, 16:365-367.
53. Thompson M.A., Aberg J.A., Cahn P., International AIDS Society-USA, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304:321-333.
54. Corbeau P., Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011, 117:5582-5590.
55. Geretti A.M., Brook G., Cameron C., BHIVA Immunization Writing Committee, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008, 9:795-848.
56. Crum-Cianflone N.F., Wilkins K., Lee A.W., Infectious Disease Clinical Research Program HIV Working Group, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011, 203:1815-1823.
57. Veit O., Niedrig M., Chapuis-Taillard C., Swiss HIV Cohort Study, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009, 48:659-666.
58. Pacanowski J., Lacombe K., Campa P., et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 2012, 59:360-367.
59. Soonawala D., Vlot J.A., Visser L.G. Inconvenience due to travelers' diarrhea: a prospective follow-up study. BMC Infect Dis 2011, 11:322.
60. Jong E.C., Freedman D.O. Chapter 8. Immunocompromised travelers. The yellow book. CDC health information for international travel 2012 2012, Oxford University Press. G.W. Brunette (Ed.).
61. Kotton C.N., Ryan E.T., Fishman J.A. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant 2005, 5(1):8-14.